Evidence map›Paper›PMID 41714374›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Identification of a novel GSK-3β inhibitor for Alzheimer's disease using In-Silico prediction and experiment cycling, validated in a streptozotocin-induced Alzheimer's disease mouse model.

Neha Chauhan, Smita Jain, Paras Gupta, Jaya Dwivedi, Sarvesh Paliwal, Swapnil Sharma, Achal Mishra, Sudarshan Singh, Mini Rani Mary Beth, Manjula Arunraj

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Neha ChauhanDepartment of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, 302022, India.
Smita JainDepartment of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, 302022, India.ORCID http://orcid.org/0000-0002-3374-5792
Paras GuptaDepartment of Pharmacognosy, United Institute of Pharmacy, Prayagraj, Uttar Pradesh, 211010, India.ORCID http://orcid.org/0009-0004-0067-2787
Jaya DwivediDepartment of Chemistry, Banasthali Vidyapith, Tonk, 302022, Rajasthan, India.
Sarvesh PaliwalDepartment of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, 302022, India.ORCID http://orcid.org/0000-0002-5247-2021
Swapnil SharmaDepartment of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, 302022, India.ORCID http://orcid.org/0000-0003-2639-7096
Achal MishraDepartment of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, 495009, India. achal.mishra03@gmail.com.
Sudarshan SinghOffice of Research Administration, Chiang Mai University, Chiang Mai, 50200, Thailand. sudarshan.s@cmu.ac.th.
Mini Rani Mary BethDepartment of Nursing, College of Applied Medical Sciences, King Faisal University, Al-Ahsa, 31982, Saudi Arabia.ORCID http://orcid.org/0000-0001-6839-8076
Manjula ArunrajDepartment of Health Information Management and Technology, College of Applied Medical Sciences, King Faisal University, Alahsa, 31982, Saudi Arabia.ORCID http://orcid.org/0000-0002-0598-6142

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GSK-3β has been a key target in Alzheimer's disease (AD) research for over two decades. To identify novel GSK-3β inhibitors, 333 compounds from the National Cancer Institute (NCI) database were screened using a validated ligand-based pharmacophore model with four essential features (two hydrogen bond acceptors, one hydrophobic, and one aromatic ring). After tapering screening with refined boundaries, two top compounds (NSC 275 and NSC 3198) were identified. Molecular docking and simulation studies confirmed their strong binding affinity to GSK-3β. ELISA analysis revealed that their half maximal inhibitory concentration (IC

Indexed as

Alzheimer DiseaseGlycogen Synthase Kinase 3 betaProtein Kinase InhibitorsAnimalsComputer SimulationDisease Models, AnimalMaleMiceMolecular Docking SimulationPharmacophoreStreptozocinGlycogen Synthase Kinase 3 betaProtein Kinase InhibitorsStreptozocinAlzheimer’s diseaseGlycogen synthase kinase-3βImmunohistochemistryPharmacophore modelingWestern blotting

Identifiers

PMID41714374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.